Liposomal Formulations In Cancer Therapy: Passive Versus Active Targeting
DOI:
https://doi.org/10.22270/ajprd.v7i2.489Keywords:
Liposomes, Targeting, Nano drug delivery systems, active targetingAbstract
In Cancer therapy, Nano drug delivery system comprising of Liposomes, are the most successful mode of treatment in present scenario which also has real time clinical application. Recently it is found that the closed bilayer phospholipid vesicles have many technical advantages over the initially used liposomal formulations. The delivery of therapeutics encapsulated in liposomes changes the biological distribution profile and improves the drug therapeutic indices of various drugs. This review article throws light onto many clinical liposomal drug delivery products. The liposome Nano drug delivery by the active and passive targeting is a boon as it can reduce the off-targeting effects. The current development is more focused on the diagnostic and clinical applications. Receptor targeted delivery systems are extensively explored for active targeting. However, these delivery systems are rarely seen in the clinical application because of conjugation chemistry and other implicit hurdles to develop this system.The development of nanocarriers in the cancer treatment have enormous potential in the medical field. Moreover, Immuno liposomes have been used in cancer treatment as attractive drug targeting vehicles. On the other hand, there are many other liposomal drug delivery systems having passive targeting mechanism for cancer treatment which are widely used due to enhanced retention and permeability of formulation. This review majorly focuses on the current challenges encountered in development of liposomal Nano drug delivery systems and its effective development for cancer treatment.
Downloads
References
2. Lalani R, Misra A, Amrutiya J, Patel H, Bhatt P, Patil SK. Approaches and Recent Trends in Gene Delivery for Treatment of Atherosclerosis. Recent patents on drug delivery & formulation. 2016; 10(2):141-55.
3. Jarboe J, Gupta A, Saif W. Therapeutic human monoclonal antibodies against cancer. Methods in molecular biology (Clifton, NJ). 2014; 1060:61-77.
4. Bhatt P, Lalani R, Vhora I, Patil S, Amrutiya J, Misra A, et al. Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: Enhanced loading efficiency and its pharmacokinetic evaluation. Int J Pharm. 2018; 536(1):95-107.
5. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nature reviews Cancer. 2005; 5(3):161-71.
6. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature reviews Drug discovery. 2005; 4(2):145-60.
7. Fay F, Scott CJ. Antibody-targeted nanoparticles for cancer therapy. Immunotherapy. 2011; 3(3):381-94.
8. Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, et al. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. The Lancet Oncology. 2012; 13(12):1234-41.
9. Vhora I, Patil S, Bhatt P, Gandhi R, Baradia D, Misra A. Receptor-targeted drug delivery: current perspective and challenges. Therapeutic delivery. 2014;5(9):1007-24.
10. Chou LY, Ming K, Chan WC. Strategies for the intracellular delivery of nanoparticles. Chemical Society reviews. 2011; 40(1):233-45.
11. Bhatt P, Khatri N, Kumar M, Baradia D, Misra A. Microbeads mediated oral plasmid DNA delivery using polymethacrylate vectors: an effectual groundwork for colorectal cancer. Drug delivery. 2015; 22(6):849-61.
12. Park YS. Tumor-Directed Targeting of Liposomes. Bioscience Reports. 2002;22(2):267-81.
13. Suthar SM, Rathva BA. DEVELOPMENT OF LIPOSOMAL FORMULATION: FROM FORMULATION TO STERILIZATION. World Journal of Pharmaceutical Research. 2019; 8(3):1561-71.
14. Bhatt P, Lalani R, Mashru R, Misra A. Abstract 2065: Anti-FSHR antibody Fab’ fragment conjugated immunoliposomes loaded with cyclodextrin-paclitaxel complex for improvedin vitro efficacy on ovarian cancer cells. Cancer Research. 2016; 76(14 Supplement):2065.
15. Allen TM. Liposomes. Opportunities in drug delivery. Drugs. 1997;54 Suppl 4:8-14.
16. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug discovery today. 2003; 8(24):1112-20.
17. Gabizon A, Goren D, Cohen R, Barenholz Y. Development of liposomal anthracyclines: from basics to clinical applications. Journal of controlled release : official journal of the Controlled Release Society. 1998; 53(1-3):275-9.
18. Benech RO, Kheadr EE, Laridi R, Lacroix C, Fliss I. Inhibition of Listeria innocua in cheddar cheese by addition of nisin Z in liposomes or by in situ production in mixed culture. Applied and environmental microbiology. 2002; 68(8):3683-90.
19. Shehata T, Ogawara K, Higaki K, Kimura T. Prolongation of residence time of liposome by surface-modification with mixture of hydrophilic polymers. Int J Pharm. 2008; 359(1-2):272-9.
20. Sharma A, Sharma US. Liposomes in drug delivery: Progress and limitations. International Journal of Pharmaceutics. 1997; 154(2):123-40.
21. Riaz M. Liposomes preparation methods. Pakistan journal of pharmaceutical sciences. 1996; 9(1):65-77.
22. Lalani R, Misra A, Amrutiya J, Patel H, Bhatt P, Patel V. Challenges in Dermal Delivery of Therapeutic Antimicrobial Protein and Peptides. Current drug metabolism. 2017; 18(5):426-36.
23. Pathak Nandish PP. Applications of liposome in cancer drug delivery and treatment: A review Asian Journal of Pharmaceutical Research and Development. 2019; 7(1):62-5.
24. Yewale C, Baradia D, Patil S, Bhatt P, Amrutiya J, Gandhi R, et al. Docetaxel loaded immunonanoparticles delivery in EGFR overexpressed breast carcinoma cells. Journal of Drug Delivery Science and Technology. 2018; 45:334-45.
25. Pathak N,Pathak P. Nanoparticles and Target Drug Delivery for Cancer Treatment: A Comprehensive Review. International Journal of Drug Regulatory Affairs.2019; 7(1):53-8.
26. Duncan R. The dawning era of polymer therapeutics. Nature reviews Drug discovery. 2003; 2(5):347-60.
27. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature reviews Drug discovery. 2008; 7(9):771-82.
28. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Molecular pharmaceutics. 2008; 5(4):505-15.
29. Liechty WB, Peppas NA. Expert opinion: Responsive polymer nanoparticles in cancer therapy. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2012; 80(2):241-6.
30. Vhora I, Patil S, Bhatt P, Misra A. Protein- and Peptide-drug conjugates: an emerging drug delivery technology. Advances in protein chemistry and structural biology. 2015; 98:1-55.
31. Lalani RA, Bhatt P, Rathi M, Misra A. Abstract 2063: Improved sensitivity and in vitro efficacy of RGD grafted PEGylated gemcitabine liposomes in RRM1 siRNA pretreated cancer cells. Cancer research. 2016; 76(14 Supplement):2063.
32. Wakaskar RR, Bathena SP, Tallapaka SB, Ambardekar VV, Gautam N, Thakare R, et al. Peripherally cross-linking the shell of core-shell polymer micelles decreases premature release of physically loaded combretastatin A4 in whole blood and increases its mean residence time and subsequent potency against primary murine breast tumors after IV administration. Pharmaceutical research. 2015; 32(3):1028-44.
33. Bhatt P, Vhora I, Patil S, Amrutiya J, Bhattacharya C, Misra A, et al. Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. Journal of Controlled Release. 2016; 226:148-67.
34. Gandhi M, Bhatt P, Chauhan G, Gupta S, Misra A, Mashru R. . IGFII-Conjugated Nanocarrier for Brain-Targeted Delivery of p11 Gene for Denhanced permeability and retention (EPR)ession. AAPS PharmSciTech. 2019; 20(2):50.
35. Ambardekar VV, Wakaskar RR, Sharma B, Bowman J, Vayaboury W, Singh RK, et al. The efficacy of nuclease-resistant Chol-siRNA in primary breast tumors following complexation with PLL-PEG(5K). Biomaterials. 2013; 34(20):4839-48.
36. Tandel H, Bhatt P, Jain K, Shahiwala A, Misra A. In-Vitro and In-Vivo Tools in Emerging Drug Delivery Scenario: Challenges and Updates. In: Misra ASA, editor. In-vitro and in-vivo tools in drug delivery research for optimum clinical outcomes. Boca Raton: CRC Press; 2018.
37. Javia A, Amrutiya J, Lalani R, Patel V, Bhatt P, Misra A. Antimicrobial peptide delivery: an emerging therapeutic for the treatment of burn and wounds. Therapeutic delivery. 2018; 9(5):375-86.
Published
How to Cite
Issue
Section
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.